CivilsIASPrep.comHealth activists seek revision of India’s essential medicines list to ensure price cap, availability
What does this development mean for UPSC preparation?
UPSC CSE Context Why in News: Civil society demands revision of India's National List of Essential Medicines NLEM after four year gap, citing WHO updates and missing cancer drugs. Syllabus Connection: GS Paper 2: Issues relating to health, government policies and interventions; GS Paper 3: Pricing of pharmaceuticals. E
UPSC CSE Context
Why in News: Civil society demands revision of India's National List of Essential Medicines (NLEM) after four-year gap, citing WHO updates and missing cancer drugs. Syllabus Connection: GS Paper 2: Issues relating to health, government policies and interventions; GS Paper 3: Pricing of pharmaceuticals. Exam Relevance: Highlights policy lag in essential medicines, price regulation, and right to health; relevant for health governance and social justice questions. ## Core Issue NLEM not updated since 2022; WHO list revised twice; missing cancer and biologic drugs. Key Development: Working Group on Access to Medicines and Treatments writes to government for urgent NLEM revision. Stakeholders:
- Ministry of Health and Family Welfare
- National Pharmaceutical Pricing Authority (NPPA)
- Patients (especially cancer and diabetes) ## Static Knowledge High-Value Background:
- NLEM is a list of essential medicines used to ensure availability and affordability; inclusion triggers price ceiling by NPPA.
- WHO Model List of Essential Medicines serves as global benchmark, updated every two years. Exam Linkage:
- Useful for questions on health policy, drug pricing, and right to health under Article 21. Concepts in Context:
- Essential medicines: drugs that satisfy priority healthcare needs, selected based on disease prevalence, efficacy, safety, and cost-effectiveness.
- Price ceiling: maximum price set by NPPA for essential medicines to ensure affordability. ## Dynamic Analysis ### Governance
- Four-year delay in NLEM revision indicates bureaucratic inertia and lack of periodic review mechanism.
- Absence of transparent, time-bound process for updating list undermines public health preparedness.
- Conflict of interest concerns if pharmaceutical industry influences list composition. ### Health
- Missing cancer drugs and monoclonal antibodies from NLEM denies patients access to modern treatments.
- Diabetes and cancer patients face higher out-of-pocket expenditure due to absence of price caps.
- India's list includes locally relevant drugs (e.g., TB) but gaps in oncology reflect global standard-of-care lag. ### Constitutional/Legal
- Price control through NLEM is a state obligation to ensure affordable healthcare; non-update weakens this commitment.
- Constitutional duty to protect life includes access to essential medicines; delay has human rights implications. ### Economy
- Price ceiling on essential medicines reduces out-of-pocket spending, crucial for low-income households.
- Non-inclusion of new drugs keeps prices high in private market, increasing financial burden on patients.
- Timely revision can stimulate generic production and competition, lowering costs. ## Mains Value Addition Arguments:
- Periodic revision of NLEM is essential to align with evolving disease burden and medical advancements.
- Price regulation through NLEM is a key tool for achieving Universal Health Coverage.
- Delay disproportionately affects vulnerable populations with chronic diseases like cancer and diabetes.
- India's list need not mirror WHO list but must address critical gaps in life-threatening conditions. Examples:
- 17 active cancer-treating agents and 4 supportive cancer-care medicines on WHO list but missing from NLEM.
- Nine monoclonal antibodies absent from NLEM despite being standard in modern cancer treatment. Data Points:
- NLEM last updated on September 13, 2022.
- WHO list expanded to 523 medicines in 2025 from 384 in India's NLEM. Counterpoints:
- Some deviation from WHO list is legitimate due to India's specific disease burden and cost considerations.
- Frequent revisions may disrupt supply chains and increase administrative burden.
- Price caps could reduce profitability, potentially discouraging production of essential medicines. ## Way Forward
- Establish a statutory timeline for mandatory NLEM revision every two years.
- Ensure transparent, conflict-of-interest-free process involving clinicians, public health experts, and civil society.
- Prioritize inclusion of missing cancer drugs and biologics based on disease burden and global evidence.
- Strengthen NPPA's capacity to enforce price ceilings promptly after NLEM update.
- Link NLEM revision with procurement and supply chain planning to ensure availability in public hospitals.
How should an aspirant use this analysis?
Connect the development to the relevant syllabus phrase, distinguish verified facts from interpretation, and use the cited source to confirm time-sensitive details. For Mains, frame the issue through stakeholders, constitutional or institutional context, implementation constraints and a balanced way forward. For Prelims, extract only testable terms, bodies, provisions, locations and cause-effect relationships.